Syntax Research’s C4 Therapeutics CCCC Stock Holding History

Syntax Research’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,000	Closed	-$1.43K	–	174
2025 Q2	$1.43K	Hold	1,000	–	–	﹤0.01%	168
2025 Q1	$1.6K	Hold	1,000	–	–	﹤0.01%	173
2024 Q4	$3.6K	Hold	1,000	–	–	﹤0.01%	172
2024 Q3	$5.7K	Hold	1,000	–	–	﹤0.01%	166
2024 Q2	$4.62K	Hold	1,000	–	–	﹤0.01%	158
2024 Q1	$8.17K	Hold	1,000	–	–	0.01%	141
2023 Q4	$5.65K	Hold	1,000	–	–	﹤0.01%	154
2023 Q3	$1.86K	Buy	+1,000	New	+$3.05K	﹤0.01%	174

Other funds holding CCCC

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Syntax Research's CCCC Position: Q3 2025 in Review

Syntax Research sold out of C4 Therapeutics (CCCC) in Q3 2025, closing a stake of 1,000 shares — an estimated $1.43K sold.

Syntax Research first reported a position in CCCC in Q3 2023 and held it in 8 quarters. The position peaked at $8.17K in Q1 2024. 97 funds tracked by Wall St. Rank hold CCCC as of Q3 2025.

Syntax Research reported no remaining C4 Therapeutics position as of Q3 2025 after selling out during the quarter.
Syntax Research sold 1,000 C4 Therapeutics shares in Q3 2025, an estimated $1.43K.
Syntax Research first reported a position in C4 Therapeutics in Q3 2023 and held it in 8 quarters.
Syntax Research's C4 Therapeutics position peaked at $8.17K in Q1 2024.
97 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2025.

Based on Syntax Research's 13F filing for Q3 2025, filed 4 Nov 2025.